Windtree Therapeutics, Inc. · OTC:WINT
Windtree Therapeutics — Investor Presentation (May 2022)
47 slides from Windtree Therapeutics's investor presentation, May 5, 2022
Slide 1: Windtree Therapeutics Company Overview
Windtree Therapeutics Company Overview WINDTREE THERAPEUTICS
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21€ of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company
Slide 3: Windtree Therapeutics Highlights
Windtree Therapeutics Highlights GS Biopharmaceutical company with advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) Clinical programs focused on significant markets with high unmet needs gw and with supportive regulatory paths: * One clinical program r
Slide 4: Windtree Therapeutics Pipeline
Windtree Therapeutics Pipeline eR FDA Fast Track Designation Potential for Breakthrough Designation FDA, EMA Orphan Drug for ROS FDA Fast Track Designation, Orphan Drug ev 2 WINDTREE Products Istaroxime (Acute Heart Failure) Istaroxime (Early Cardiogenic Shock) Oral SERCA2a Activators (Chronic HF; p
Slide 5: Strategy for Value Creation
Strategy for Value Creation < Meet w/FDA; EMA Phase2 SEISMIC Extension Study ¢) > (seismic) —— ; Results SCAI Stage C Study Istaroxime Acute Heart Failure Study ~18 months to execute; €0P2 Mis A Heart Failure {transition to Phase 3)** eS ree d Oral SERCA2a Activator Heart Failure Agents; Pre-Clinica
Slide 6: Istaroxime
Istaroxime Dual Mechanism SERCA2a Activator Acute Heart Failure and Early Cardiogenic Shock | Se winoTREE ae
Slide 7: Heart Failure — Large, Growing Market But Underserved
Heart Failure — Large, Growing Market But Underserved The prevalence and mortality of heart failure is high and increasing > 6MU.S., 20M+ worldwide patients v #1 cause of U.S. hospitalization in patients > 65 years old; * >1,3M admissions annually (U.S.) “1.5M admissions annually (E.U.) > In-patient
Slide 8: Acute Heart Failure — Significant Unmet Clinical Need
Acute Heart Failure — Significant Unmet Clinical Need = Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g., “dry out”) with IV diuretics * Improve cardiac function and peripheral/organ perfusion * Achieve stable, fully compensated clinical
Slide 9: Istaroxime — Novel First-in-Class Therapy
Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart Oss, aA Tahibidon of the scatana- Stimulation of SERCA2a activity — enhances calcium reuptake resulting in potassium pumpandetfectson ISEAFOXTME improvemen
Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary
Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients a & oO n=120 Dosing= 6 hour Phase jor patients 0.5, 1, 1.5 ve/te/nin Infusion Phase n=120 Dosing= 24 hour ADHF Patients 0.5, 1.0 us/ie/min Infusion (dyspnea plus need for IVfu
Slide 11: Primary Endpoint Achieved
Primary Endpoint Achieved Significant Changes in E/e' Ratio) and Stroke Volume Istaroxime 0.5 ug/kg/min vs. placebo Istaroxime 1.0 yg/kg/min vs. placebo B20 B20 3 Efe’ 3 0 so | tus peed Tafsion period * * * ples “° " * ple = 038 ‘ rales 0.034 Denne Shoots ts cecne hans hes thos na rc-cnen ezrcineo s
Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve
Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve Istaroxime 0.5 ug/kg/min vs. placebo Istaroxime 1.0 ug/kg/min vs. placebo —————— ———— : : E Systolic = 3 Blood = * 4 Pressure = ° d+ (sBP) a4 * eee | “i * p-value =0.011, ** p-values $0.006 eet grat gate watt gra
Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins
Heart Rate Decreased and No Increases in Cardiac Troponins Istaroxime 0.5 ug/kg/min vs. placebo . 3 Aa oa Zo Heart 53 Rate Es 59 Par * pvalue= 0.014 Cas SS Se SS SS PPO Oot == Plocevo-Cohet 1 ge ineroxineD ualke/min cTnT — 0 to 24 hours a Cardiac TaT é (Myocardial SS Damage) 68 0 Placebo cohort? Ist
Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring
Favorable Profile Observed with 24-hour Holter Monitoring Clinically Significant Arrhythmias: Clinically Significant Arrhythmias. ee 200% sad 15.0% I = Te Os Us se I L Ventricular Tachycardia Ventricular Tachycardia bean ary be ‘60.0% BOON O08 40.0% best S008 vce (nt/24 hours) shown as me ventricula
Slide 15: Istaroxime — Acute Heart Failure Next Steps
Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 60 centers globally* Enrich therapeutic impact
Slide 16: Istaroxime Early Cardiogenic Shock
Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development
Slide 17: Cardiogenic Shock
Cardiogenic Shock Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > Caused by severe impairment of cardiac function that results in diminished cardiac output, end-organ hypoperf
Slide 18: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity to Address Significant Unmet Need > No satisfactory pharmacological intervention to reverse the conditions * Available therapies have unwanted side effects such as risk for arrhythmias, decreasing blood pressure, renal dysfunction an
Slide 19: Early Cardiogenic Shock Treatment
Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Pathway Sponsors are potentially not required to show benefit other than an increase in blood pressure to support approval of drugs to treat hypotension in the setting of shock!) FDA Regulatory (Precedent: NDA for Gia
Slide 20: Changes in SBP — Phase 2a and 2b Dose Groups
Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 20.0 18.0 16.0 14.0 12.0 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study 0.5 yg/kg/min 1.0 pig/kg/min 1.5 ug/kg/min Study/Dose SE (mmHg) + SBP Mean Change ‘Mean S
Slide 21: SEISMIC Early Cardiogenic Shock Study
SEISMIC Early Cardiogenic Shock Study Early cardiogenic shock study: Clinical strategy: Start development with patients in early cardiogenic shock caused by severe heart failure —& 60 patients in early cardiogenicshock (SBP 75-90mmHg) with AHF in the EU and US Study drug was infused for 24 hours in
Slide 22: Topline Study Results
Topline Study Results SEISMIC was a Positive Study in SCAI Stage B Early Cardiogenic Shock Patients = The study met its primary endpoint in SBP profile over six hours, with the istaroxime treated group performing significantly better compared to the control group. = Further details of study results
Slide 23: SEISMIC Extension Study
SEISMIC Extension Study (amendment to the ECS study) Following the positive results in the early cardiogenic shock study, an extension study is planned to support ongoing development in early cardiogenic shock and acute heart failure Study objectives: v Advance the characterization of the physiology
Slide 24: Planned SCAI Stage C Cardiogenic Shock Patient Study
Planned SCAI Stage C Cardiogenic Shock Patient Study While a smaller group than SCAI stage B, given positive results in early cardiogenic shock, the strategy is to gain experience in more severe, SCAI stage C patients to support both regulatory, development and commercial strategies Study objectives
Slide 25: SEISMIC Trial — Relevance to the AHF Program
SEISMIC Trial — Relevance to the Acute Heart Failure (AHF) Program = The early cardiogenic shock trial results are consistent with Windtree’s Phase 2 AHF studies and complementary to further advancement in AHF. = While SEISMIC was an early cardiogenic shock study, the patients studied had very sever
Slide 26: Next Steps for Early Cardiogenic Shock and the Year Ahead
Next Steps for Early Cardiogenic Shock and the Year Ahead for Windtree = Plan to present more data from SEISMIC at the European Society of Cardiology (ESC) Heart Failure Meeting in May of 2022 and publish the trial results = Start the Dose Extension Study to further optimize the dosing regimen for t
Slide 27: Next Generation, Oral SERCA2a Activators
Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCA2a Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation istarox
Slide 28: Lyo Lucinactant
Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in Vg COVID-19 Patients ®
Slide 29: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function
COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Uses angiotensin- ACEZis surface molecule on Surfactar lungs to stay Serwerting enzyme? alveolar Type 2lung cells~ _ inflated and for proper gas exchange: (ACE2) for entry into host _the source of surfactant Type
Slide 30: Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 ARDS
Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 ARDS Objective: Demonstrate safe and tolerable surfactant administration and changes in physiological parameters in COVID-19-associated lung injury and ARDS a * Open-label, single arm study in 20 patients from sites in US and La
Slide 31: AEROSURF
AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS)
Slide 32: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli
Slide 33: AEROSURF — Potential to Impact the Clinical Course of RDS
AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Study results show Parameters evidence of potential impact on clinical course of RDS and respiratory health of preterm infan
Slide 34: AEROSURF Program Evolution and Strategy
AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach “1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2/Phase 3: + Demonstrate that new ADS works and supplement Phase 2 data + Optimize dosing with more drug and shorter repeat intervals Y Transition
Slide 35: Financial Summary & Capitalization as of March 31, 2022
Financial Summary & Capitalization as of March 31, 2022 = Cash & Equivalents of ~$15.5 million Common Equivalents Secu . as of May 5, 2022 Common Stock 29,406,172 Options (WAEP $7.81) 4,163,934 Restricted Stock Units 554,000 Warrants (WAEP $9.43) 16,628,802 Fully Diluted Equivalents 50,752,908 WINDT
Slide 36: Strategy for Value Generation
Strategy for Value Generation se we WINDTREE THERAPEUTICS GS Communicate Our Milestones: Share the results from our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts - set new milestones for the future G Transactions: * Secure focused BD transactio
Slide 37: Windtree Therapeutics
Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” Se winoTREE ae
Slide 38: Appendix
Appendix SQwinotree
Slide 39: Acute Heart Failure
Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need * Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state
Slide 40: Istaroxime Phase 2a (HORIZON-HF) Study
Istaroxime Phase 2a (HORIZON-HF) Study se @ Rp e = Multicenter, double blind, placebo- controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% © SBP 90-150 mmHg = N=120 (30/group) = Significant improv
Slide 41: Istaroxime Phase 2b Adverse Events
Istaroxime Phase 2b Adverse Events Istaroxime 0.5 Istaroxime 1.0 wa EP melon menace (n=41) a) ‘All adverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to ere 1 (2.6%) : 4 (10.0%) Serious adverse events 2 (5.1%) 2 (8.9%) 6 (15.0%) Cardiac death : : 4 (2.5%) Cardiogenic shock : 5 1
Slide 42: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study
KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur
Slide 43: Evidence of KL4 Surfactant Potential Utility in COVID-19
Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic jonstrated Utility of K
Slide 44: Respiratory Distress Syndrome (RDS)
Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange t Initial treatment options include = invasive and noninvasive methods:
Slide 45: Windtree Technology Platform — AEROSURF
Windtree Technology Platform — AEROSURF® Proprietary Synthetic e KLa Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) titcy 3 aerosolize Kia surfactant for RDS approved by the FDA lyop
Slide 46: Transformative Potential of AEROSURF
Transformative Potential of AEROSURF® Surfactant nCPAP Therapy Respiratory Support Reversing surfactant deficiency has a profound positive impact on Avoids exposure to the risks respiration of invasive delivery of, surfactant therapy Surfactant therapy delivers near-immediate clinical improvement} B
Slide 47: Business Development Focus
Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Mid-term Heart Failure Portfolio Partner — Global (Data & EOP2) Rosta Out
Windtree Therapeutics — Investor Presentation (May 2022) on 6ix